However, other studies described that in postmenopausal ER + breast cancer patients, AR expression was not associated with prognosis, and the authors suggested that AR expression may not be an informative biomarker for the selection of adjuvant endocrine therapy [142]. The gene discussed is ESR1; the disease is breast cancer.